Target intelligence / Profile preview

Heterogeneous nuclear ribonucleoprotein A1 pseudogene 17 (HNRNPA1P17)

Target
HNRNPA1P17
Molecular classification
Other (Pseudogene)
01

Overview

Heterogeneous nuclear ribonucleoprotein A1 pseudogene 17 (HNRNPA1P17) is a non-protein-coding pseudogene related to the HNRNPA1 gene, which encodes a member of the heterogeneous nuclear ribonucleoprotein A/B family. Pseudogenes like HNRNPA1P17 are genomic DNA sequences similar to known genes but typically contain mutations preventing functional protein production. While some pseudogenes can have regulatory roles at the RNA level, there is no published evidence of specific biological activity, disease association, or therapeutic relevance for HNRNPA1P17 itself[1][4][5]. Supporting details and context: - HNRNPA1P17 is explicitly annotated as a "pseudogene" in all authoritative resources and gene databases[1][4][5]. - Pseudogenes are generally not considered valid therapeutic targets, as they do not code for functional proteins[2]. They may, in some cases, play a role in gene regulation or serve as competitive endogenous RNAs, but there is currently no published evidence for such functions specifically attributed to HNRNPA1P17[2][5]. - There are no drugs, mechanisms of action, biomarker status, or safety concerns directly linked with HNRNPA1P17[5]. - On classification: HNRNPA1P17 falls under "Other" for molecular classification, as it is a pseudogene, not a receptor, enzyme, transporter, etc.[5] Assessment of validity: - is_incorrect: true, as this is not a therapeutic or functional molecular target. It is a pseudogene lacking experimental evidence for protein-coding function or direct involvement in disease/therapy; thus, requesting drug or target-related information for HNRNPA1P17 is not applicable[1][5]. - If the intent was to refer to the protein Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1), that is a regulated protein with functional and disease relevance, but HNRNPA1P17 is a distinct, noncoding pseudogene[6][3]. Summary: HNRNPA1P17 is a noncoding pseudogene, not a protein, receptor, or drug target, with no documented function, disease role, or therapeutic relevance. All valid information for structured curation is provided above.

Other names
HNRNPA1P17HNRNPA1 pseudogene 17
02

Biological functions

Other (No protein product; may have regulatory RNA function as per general pseudogene literature but none specifically characterized for HNRNPA1P17)
03

Disease associations

Other (No direct evidence of disease association; possible relevance if transcriptionally active per general pseudogene findings)

Beyond the preview

Go deeper on Heterogeneous nuclear ribonucleoprotein A1 pseudogene 17 (HNRNPA1P17).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein A1 pseudogene 17 (HNRNPA1P17).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call